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Summary
Objectives: In order todetermine the risk factors for rectal colonizationwith vancomycin-resistant
enterococci (VRE) at the Shiraz Namazi Hospital, we performed a nested case—control study.
Methods: From December 2003 to July 2004 rectal swabs were taken from 700 randomly selected
hospitalized patients every 5 days.
Results: A total of 99 of the 700 patients (14%) were colonized with VRE (cases) and 59 patients
were colonized with vancomycin-sensitive strains (VSE), serving as controls. In the univariate
analysis, history of antibiotic use (p = 0.04), underlying disease (p = 0.013), hemodialysis
(p = 0.03), use of third generation cephalosporins (p = 0.04), use of vancomycin (p = 0.04),
and duration of vancomycin therapy longer than 7 days (p = 0.02) were significantly associated
with VRE colonization. In a multivariate analysis, underlying disease and the duration of vanco-
mycin use longer than 7 days were independently associated with VRE colonization.
Conclusion: Our study, the first on VRE carriage in Iran, demonstrates that VREprevalence is high in
Shiraz and confirms earlier observations in other countries. The identified risk factor ‘use of
vancomycin longer than 7 days’ may be avoidable, indicating a feasible intervention strategy in the
control of VRE.
# 2007 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
The worldwide observed increase in antimicrobial resistance
among pathogens causing nosocomial infections constitutes a* Corresponding author. Tel.: +98 917 1125777;
fax: +98 711 2354431.
E-mail address: askariam@sums.ac.ir (M. Askarian).
1201-9712/$32.00 # 2007 International Society for Infectious Diseases.
doi:10.1016/j.ijid.2007.04.020major public health problem.1 One of the best examples of
the bacterial quest for survival are enterococci. For years
viewed as harmless inhabitants of the intestinal flora, enter-
ococci have acquired resistance to multiple antibiotics, mak-
ing glycopeptides like vancomycin one of the last available
compounds for therapy. Vancomycin-resistant enterococci
(VRE) are among the most feared pathogens in hospitals in
the USA. However, the epidemiology of VRE in Europe and
America appears to be very different. In contrast to thePublished by Elsevier Ltd. All rights reserved.
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VRE remain uncommon in Europe.2 The US National Nosoco-
mial Infection Surveillance (NNIS) system has revealed a
significant increase in the percentage of nosocomial Enter-
ococcus spp strains displaying vancomycin resistance. The
figure for the incidence of VRE in intensive care unit (ICU)
patients rose from 0.4% in 1989 to 23.4% in 1997. In non-ICU
patients, the percentage increased from 0.3% to 15.4%,
representing a 50-fold increase in a relatively short time
span.3 According to data from the NNIS system, enterococci
are now the fourth leading cause of nosocomial infections
and the third in ICU patients in the USA.1,4,5
Risk factors for VRE colonization may be patient-, hospi-
tal-, environment-, and antibiotic-related.1 Although many
studies have been performed in Europe and the USA on the
prevalence, incidence, epidemiology, and risk factors of VRE,
data for the Middle East and Asia are scarce.6 This study is the
first investigation on the epidemiology of VRE in Iran. The aim
of the present study was to determine the prevalence and
risk factors of rectal colonization with VRE in Iranian
patients.
Materials and methods
Setting
The study hospital (Shiraz Namazi Hospital) provides primary
and tertiary care in a 750-bed health facility for patients
admitted from Shiraz, Fars State and other southern states of
Iran. Twenty-five wards participated in this study, including
nine ICUs with a total capacity of 50 beds (two neurosurgical
ICUs, two medical ICUs, one surgical ICU, one pediatric ICU,
one neonatal ICU, and two cardiac care units), five surgical
wards with a total of 120 beds (neurosurgery, plastic surgery,
general surgery, urology, and trauma), seven medical wards
with a total of 135 beds (one cardiology, one female medical
ward, one male medical ward, two general medical wards,
and two oncology wards), and four pediatric wards with a
total capacity of 80 beds (three medical wards and one
surgical ward).
Currently, there are no VRE-specific infection control
strategies implemented in the investigated hospital, and
no screening policy or surveillance concepts. There are,
however, general measures including hand hygiene and stan-
dard precaution concepts, although compliance varies.
Patients
All hospitalized patients admitted during the study period
(December 2003 through July 2004) with a hospital stay of
longer than 5 days (700 patients) were selected for this study.
Study design
This study was designed as a nested case—control and
descriptive-analytic study to determine the prevalence
and risk factors of colonization with VRE. Educated nurses
took serial rectal swabs every 5 days. Samples were sent to
the laboratory in transportation tubes (Venturi Transystem,
Copan Diagnostics Inc., New York, NY, USA). A case patient
was defined as any patient who had a positive sample yieldingVRE; a control patient was a patient from whom vancomycin-
sensitive enterococci (VSE) were yielded. A third group
encompassed all patients with repetitive negative Entero-
coccus spp samples.
Data collection
Data from each patient were extracted from the medical
records and at the bedside. Obtained data included the
following: age, sex, co-morbidity and underlying disease,
ward of admission, duration of stay, prior admission, prior
antibiotic use, clinical outcome, kind and duration of anti-
biotic use before colonization, and laboratory results.
Microbiological methods
Rectal swab specimens were cultivated on a selective agar
and incubated at 37 8C overnight. Cephalexin—aztreonam—
arabinose agar (CAA) was prepared by adding 40 g of Colum-
bia agar base (Unipath, Basingstoke, UK), 10 g of arabinose
(Sigma Chemical Co., Poole, UK), and 3.6 ml of phenol-red
(2%; BDH, Lutterworth, UK) to 1 liter of de-ionized water. The
medium was mixed and the pH was adjusted to 7.8. The agar
was autoclaved at 114 8C for 20 min. Fresh sterile solutions of
aztreonam (Bristol-Myers Squibb, Hounslow, UK) and cepha-
lexin (Sigma) were added to give final concentrations of
75 mg/l and 50 mg/l, respectively.7
Swabs were streaked on the surface of CAA. The plates
were incubated at 37 8C in air for 24 h and examined for
growth and fermentation of arabinose. A change in the color
of the medium surrounding the colony, from red to yellow,
indicated arabinose fermentation.
Conventional organism identification and
susceptibility testing
Red to yellow colonies resembling enterococci on the CAA
plates were further identified by conventional laboratory
methods, including Gram staining and determination of colo-
nial morphology and biochemical and growth characteris-
tics.8,9 Species identification was performed using API 20
STREP (bioMerieux, Marcy L’Etoile, France). In vitro suscept-
ibility to ampicillin, penicillin, gentamicin, vancomycin, and
teicoplanin was tested according to Clinical and Laboratory
Standards Institute (CLSI, formerly NCCLS)10 guidelines, using
the agar dilution method and Mueller—Hinton agar (Becton
Dickinson, Franklin Lakes, USA).
Definitions
The presence of the following conditions was documented for
underlying disease: immunosuppression, neutropenia, renal
failure (as indicated by baseline creatinine level of>0.2 mg/
dl), hemodialysis, cancer, diabetes mellitus, major surgery,
severe cardiac disease (as indicated by cardiac heart failure
and myocardial infarction), sepsis, and systemic lupus
erythematosus (SLE). Prior admission was defined as admis-
sion during the six months before the present hospitalization.
Prior antibiotic use was defined as the administration of
antimicrobials for >72 h during the 60 days before the onset
of hospitalization. Duration of antibiotic use before coloniza-
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before colonization with VRE or VSE, for antibiotic use of
more than 1 day. The duration of hospitalization was the
number of days a patient was cared for at the institution
determined by enumeration of hospital days per patient,
regardless of VRE or VSE status. Colonization was defined
as the isolation of VRE or VSE from a rectal swab culture with
or without evidence of clinical infection with the yielded
organism. A negative baseline culture with more than one
positive follow-up culture was considered acquisition.
Statistical analysis
Data were analyzed using SPSS (Statistical Package for Social
Sciences) software. Qualitative variables were compared by
use of Pearson’s Chi-square test or Fisher’s exact test, and
quantitative variables were compared by Mann—Whitney U-
test. Univariate analysis of risk factors for colonization and
acquisition was performed. All p values were on two-sided
test ( p < 0.05). A logistic regression model was built to
identify risk factors. Variables with p < 0.25 were retained
in the final model. Odds ratios and the corresponding 95%
confidence intervals were calculated using the results
obtained for the maximum likelihood estimates.11
Ethical considerations
Informed oral consent was obtained from all study patients
prior to specimen collection. Patients who did not
permit sampling, or patients for whom the performing of
a rectal swab was contraindicated, were not included in
the study.
Results
During the study period, a total of 700 patients out of a total
of 1856 admitted patients were enrolled into the study,
yielding more than 1000 rectal swabs (median of swab per
patient = 1). The mean age of patients was 36.4 years (range
0.02—92 years); 311 (44.4%) were female. Of these patients,
542 (77.4%) had no colonization. Ninety-nine patients (14.1%)
were VRE-colonized (case group) and 59 (8.4%) were VSE-
colonized (control group). All 99 VRE positive patients were
VRE negative on admission and became colonized during their
hospital stay. All VRE isolates were resistant to ampicillin,
penicillin, and gentamicin according to CLSI standards. How-
ever, none of the VRE positive patients developed infection
during the observation time of the study.
The results of univariate and logistic regression analysis are
shown in Table 1. In the univariate analysis, sex (p = 0.074),
ward (p = 0.17), duration of hospitalization (p = 0.11), history
of prior hospitalization (p = 0.16), and clinical outcome
(p = 0.06) were not associated with VRE colonization. How-
ever, prior administration of antibiotics (OR 3.09; 95% CI 1.82—
7.64; p = 0.04), underlying disease (OR 2.46; 95% CI 1.23—5.7;
p = 0.013), hemodialysis (OR 3.87; 95% CI 1.1—13.8; p = 0.03),
use of third generation cephalosporins such as ceftizoxime,
ceftriaxone, and cefixim (OR 2.28; 95% CI 1.1—4.9; p = 0.04),
vancomycin use (OR 2.53; 95% CI 1.1—5.8; p = 0.04), and
duration of vancomycin use longer than 7 days (OR 1.7; 95%
CI 1.1—3.4; p = 0.02) showed significant differences between
VRE- and VSE-colonized patients.In the multivariate analysis, significant independent risk
factors for VRE versus VSE colonization were only the pre-
sence of an underlying disease (OR 2.43; 95% CI 1.2—4.9;
p = 0.013) and vancomycin use for longer than 7 days (OR 1.6;
95% CI 1.0—2.5; p = 0.03).
Discussion
Vancomycin-resistant Enterococcus faecium and Enterococcus
faecalis (VRE) were first described in the UK in 198812 and soon
afterwards reported from other European countries13 and the
USA.14 Since then, VRE has steadily emerged as an important
cause of hospital-acquired infection. Gastrointestinal coloni-
zation is the most common source for VRE spreading.15 Altho-
ughmany studies have been conducted on the epidemiology of
VRE,16—19 there are few case—control studies determining risk
factors for colonization.1,12,20—22 To our knowledge, the pre-
sent study is the first study on the epidemiology of VRE in Iran.
In this study, themean age of patients showedno significant
difference between the three groups — patients without
colonization, patients with VRE colonization, and patients
with VSE colonization. However, age stratified into four groups
showed borderline significance (p = 0.052), and VRE coloniza-
tion was highest in patients aged 1—16 years, which is con-
sistent with the findings of previous investigators.23,24
Sex, ward, duration of hospitalization, and prior admis-
sion were not significant risk factors for VRE colonization.
Other investigators have also confirmed these findings for
other parts of the world. van den Braak et al.25 and Tornie-
porth et al.1 reported that sex was not associated with VRE
colonization. From our results the median length of hospi-
talization before colonization in case and control groups was
similar, which is consistent with van den Braak et al.25 and
Bertrand et al.,5 but not with Tornieporth et al.1 In our study,
all VRE positive patients were VRE negative on admission, and
80% of these patients were colonized early in the first week of
hospitalization, indicating that very early nosocomial trans-
mission occurred. Therefore, it is not surprising that duration
of hospitalization did not show as a significant risk factor,
similar to other studies.2,5,26
Prior use of antimicrobial therapy, including vancomycin
and cephalosporin, has been shown to be associated with
acquisition of VRE.1,20,22,26—28 In our study, this factor was
also significant ( p = 0.04) and increased the risk for VRE
colonization 3-fold.
Also, the presence of underlying disease was significantly
associated with an increased risk for VRE colonization, as was
the association between renal failure and hemodialysis. Of
note, impaired renal function and hemodialysis have been
previously implicated as risk factors in VRE outbreaks.29,30
Although other underlying diseases such as septicemia, immu-
nosuppression, neutropenia, malignancy, diabetes mellitus,
lupus, cardiac disease, andmajor surgery weremore frequent
in the case group than in controls, these were not significant.
However, it can be speculated that a larger sample size would
have revealed differences at the 0.05-significance level.
In the present study, use of vancomycin or a third gen-
eration cephalosporin was a significant risk factor for VRE
colonization. The use of vancomycin increased the risk of
colonization 2.5-fold and third generation cephalosporins 2-
fold. These findings are consistent with previously reported
findings.20,22,24,28,31
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Table 1 Risk factors for vancomycin-resistant Enterococcus in hospitalized patients; Shiraz Namazi Hospital, 2004
Variable Frequency (%) or mean  SD Univariate analysis Logistic regression
Cases (N = 99) Controls (N = 59) OR (95% CI) p OR (95% CI) p
Age 37.8  26.9 36.8  25.9 0.800
Stratified age 0.052 0.950
<1 year 5 (5.1) 8 (13.6)
1—16 years 18 (18.2) 4 (6.8)
16—65 years 52 (52.5) 36 (61.0)
>65 years 24 (24.2) 11 (18.6)
Sex 0.074
Male 50 (50.5) 28 (47.5)
Female 49 (49.5) 31 (52.5)
Ward 0.170 0.140
Specific 8 (8.1) 8 (13.6)
Surgical 9 (9.1) 10 (16.5)
Medical 67 (67.7) 30 (50.8)
Pediatric 15 (15.2) 11 (18.6)
Duration of hospitalization 0.890
Before colonization 6.6  3.3 6.3  3.6 0.120
Total 21.4  18.5 18.3  10.5 0.110
Prior hospitalization 36 (36.4) 15 (25.4) 0.160
Prior antibiotic use 31 (31.3) 8 (13.6) 3.09 (1.82—7.64) 0.04
Outcome 0.060
Dead 13 (13.2) 8 (13.6)
Cured 43 (43.4) 30 (50.8)
Ill and alive 43 (43.4) 21 (35.6)
Underlying disease 75 (75.7) 33 (55.9) 2.46 (1.23—5.7) 0.013 2.43 (1.2—4.9) 0.013
Immunosuppression 9 (9.1) 9 (15.3) 0.300
Neutropenia 4 (4.0) 2 (3.4) 0.060
Hemodialysis 17 (17.2) 3 (5) 3.87 (1.1—13.8) 0.030 0.060
Cancer 17 (17.2) 12 (20.3) 0.670
Major surgery 9 (9.1) 4 (6.8) 0.770
Diabetes mellitus 12 (12.1) 5 (8.5) 0.600
Cardiac disease 15 (15.2) 6 (10.2) 0.470
Sepsis 17 (17.2) 4 (8.2) 0.090
Systemic lupus erythematosus 6 (6.1) 2 (3.4) 0.710 0.390
Antibiotics
Vancomycin 31 (31.3) 9 (15.3) 2.53 (1.1—5.8) 0.040 0.730
Third generation cephalosporin 83 (83.8) 41 (69.5) 2.28 (1.1—4.9) 0.040 0.150
Aminoglycosides 32 (32.3) 19 (32.2) 1.000
Clindamycin 8 (8.1) 8 (13.6) 0.290
Metronidazole 30 (30.3) 21 (35.6) 0.590
Ciprofloxacin 18 (18.2) 6 (10.2) 0.250
Co-trimoxazole 7 (7.1) 8 (13.6) 0.260
Erythromycin 2 (2.0) 1 (1.7) 1.000
Penicillin 6 (6.1) 4 (6.8) 1.000
Duration of antibiotics used before colonization >7 days
Vancomycin 4.4  12.4 1.4  4.6 1.7 (1.1—3.4) 0.020 1.6 (1.0—2.5) 0.030
Third generation cephalosporin 8.2  9.3 6.2  6.4 0.130 0.780
Aminoglycosides 3.9  1.1 1.9  3.7 0.820
Clindamycin 0.4  1.6 0.6  1.9 0.280
Metronidazole 3.4  11.6 3.4  5.7 0.330
Ciprofloxacin 2.7  1.3 0.8  2.8 0.180
Co-trimoxazole 1.0  4.5 0.9  2.6 0.210
Erythromycin 0.2  1.3 0.1  0.5 0.880
Penicillin 0.5  2.0 0.6  2.8 0.850
OR, odds ratio; CI, confidence interval.
Risk factors for rectal colonization with VRE, Iran 175In summary, this study demonstrates that the prevalence
of VRE is high in Shiraz Namazi Hospital. Univariate analysis
suggests that prior antibiotic use, the presence of underlying
disease, hemodialysis for renal failure, administration of
vancomycin and third generation cephalosporins, and dura-
tion of vancomycin use are risk factors for VRE colonization.
However, logistic regression showed that only presence of
underlying disease, notably patients requiring hemodialysis,
and the use of vancomycin are independent risk factors for
VRE colonization.
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